This article features Roche’s option on Antisoma products. Roche will gain the rights to four compounds in Antisoma’s clinical pipeline and also secure an option on six of its discovery stage projects over 5 year period. The article also features how the biotech companies mould their operations to accommodate the requirements of a chosen pharma partners.